These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1576626)

  • 1. Loracarbef versus cefaclor in the treatment of cystitis and asymptomatic bacteriuria.
    Iravani A
    Clin Ther; 1992; 14(1):54-63. PubMed ID: 1576626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loracarbef (LY163892) versus cefaclor in the treatment of acute bacterial bronchitis.
    Dere WH; Farlow D; Therasse DG; Ruoff GE
    Clin Ther; 1992; 14(1):41-53. PubMed ID: 1576625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative trials of cefaclor AF in uncomplicated cystitis and asymptomatic bacteriuria.
    Hamilton-Miller JM; Iravani A; Brumfitt W; Byers KS; Dere WH
    Postgrad Med J; 1992; 68 Suppl 3():S60-6; discussion S66-7. PubMed ID: 1287620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
    Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loracarbef versus cefaclor in the treatment of urinary tract infections in women.
    Iravani A
    Antimicrob Agents Chemother; 1991 Apr; 35(4):750-2. PubMed ID: 2069382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia.
    Hyslop DL; Jacobson K; Guerra FJ
    Clin Ther; 1992; 14(2):254-67. PubMed ID: 1611648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis.
    Hyslop DL; Bischoff W
    Am J Med; 1992 Jun; 92(6A):86S-94S. PubMed ID: 1621752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population.
    McCarty J; Ruoff GE; Jacobson KD
    Am J Med; 1992 Jun; 92(6A):80S-85S. PubMed ID: 1621751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of a five-day regimen of cefdinir with a seven-day regimen of loracarbef for the treatment of acute exacerbations of chronic bronchitis.
    Paster RZ; McAdoo MA; Keyserling CH; Nemeth MA; Tack KJ; Griffin TJ
    Int J Clin Pract; 2000 Jun; 54(5):293-9. PubMed ID: 10954955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
    Dere WH; Farlow D; Therasse DG; Jacobson KD; Guerra FJ
    Clin Ther; 1992; 14(2):166-77. PubMed ID: 1611641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic therapy for urinary tract infections.
    Iravani A; Bischoff W
    Am J Med; 1992 Jun; 92(6A):95S-100S. PubMed ID: 1621753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group.
    Clin Infect Dis; 1995 Mar; 20(3):507-13. PubMed ID: 7756468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefaclor therapy in uncomplicated cystitis.
    Asvanich K; Fugpholngam V; Srimuang S; Tanphaichitra D
    J Med Assoc Thai; 1997 Nov; 80(11):742-5. PubMed ID: 9385773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive safety profile of cefaclor AF in respiratory, urinary tract and skin infections.
    Stotka JL; Senetar JE; Therasse DG; Dere WH
    Postgrad Med J; 1992; 68 Suppl 3():S73-7; discussion S78-80. PubMed ID: 1287622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefprozil versus cefaclor in the treatment of acute and uncomplicated urinary tract infections. Cefprozil Multicenter Study Group.
    Iravani A; Doyle CA; Durham SJ; Wilber RB
    Clin Ther; 1992; 14(2):314-26. PubMed ID: 1611652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loracarbef vs. cefaclor in pediatric skin and skin structure infections.
    Hanfling MJ; Hausinger SA; Squires J
    Pediatr Infect Dis J; 1992 Aug; 11(8 Suppl):S27-30. PubMed ID: 1513609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefaclor versus ampicillin for outpatient treatment of urinary tract infections.
    Baraff LJ; Ablon WD
    Am J Emerg Med; 1984 Jul; 2(4):327-30. PubMed ID: 6394004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sickness-like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef.
    Kearns GL; Wheeler JG; Rieder MJ; Reid J
    Clin Pharmacol Ther; 1998 Jun; 63(6):686-93. PubMed ID: 9663184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection.
    Leigh AP; Nemeth MA; Keyserling CH; Hotary LH; Tack KJ
    Clin Ther; 2000 Jul; 22(7):818-25. PubMed ID: 10945508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-comparative open study of the efficacy and tolerance of cefaclor in the prevention of urinary tract infections in children].
    Seracini D; Materassi M; Danti A
    Pediatr Med Chir; 1996; 18(4):383-5. PubMed ID: 9064670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.